HCC Staging Modified by Tumor Micronecrosis

Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

primary and histologically confirmed HCCs
patients who underwent curative liver resection

Exclusion criteria

simultaneous presence of other tumors
patients who had received preoperative antitumor therapies
no available surgical specimens for evaluating micronecrosis status
gross tumor necrosis and Nscore = 3

Treatment and study plan

tumor micronecrosis

Behavioral

whether HCC patients have tumor micronecrosis or not

Primary outcomes

Overall survival

Time frame: from date after liver resection until death or last follow-up, whichever came first, assessed up to 72 months

the number of months from the date of surgery to the date of the last follow-up visit or time of death.

Secondary outcomes

Disease-free survival

Time frame: from date after liver resection until recurrence or last follow-up, whichever came first, assessed up to 72 months

the number of months from the date of surgery to the date of first confirmable recurrence or death

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Collaborators

Huizhou Municipal Central Hospital
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Second Affiliated Hospital of Nanchang University

Registry information

Official study title

Optimizing Hepatocellular Carcinoma Disease Staging Systems by Incorporating Tumor Micronecrosis: A Multi-institutional Retrospective Study

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2023
First posted: Feb 22, 2023
Registry last updated: Feb 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed